Kraków, 18.05.2011
A presentation (in Polish) given to Cracow Technology University as a part of series of lectures to commemorate the 45th Anniversary of the Department of Chemical Engineering and Technology there.
Case 1 (Strategy formulation: must not be viewed as a description of true Orlen Oil story). Imagine the middle-size company facing a double challenge: big Internationals ale pushing technological edge beyond capacities of smaller players, minors are competing on price for diminishing, low segments of the market. Basically both ways of competing as prescribed by Porter (eg. by product differentiation or price) are already taken and well fenced. The typical answer (how many times you have heard it?) is: “rigid costs control” and “concentration on profitable segments”. There are only two “buts”:
Expert was appointed by the General Meeting of PAEE held 2022/05/31 a member of the Audit Committee./ Ekspert został nominowany do Komisji Rewizyjnej PAEE na Zgromadzeniu Członków Stowarzyszenia w dniu 31 maja 2022 r.
ACADEMIC PUBLICATIONS ON STRATEGY & ENERGY RELATED ISSUES
PUBLICATIONS
Case 2: Creation of joint Oren Oil and academic technology transfer programs. Having identified that one of the strategic disadvantages of Orlen Oil was lack of direct access to technology research programs which cornered the company to buy on-shelf solutions available virtually to everybody on the market and consequently made the company a cost based player the decision was taken to step into basic research area. Being aware of various studies related to tribology and lubricating issues carried out by Polish academic and research institutions we teamed up a group of 5 employees who undertook a constant task of identifying institutions pursuing projects/programs of interest to Orlen Oil. An adequate set of criteria had been developed which included, among others, compatibility of research fields to lubricating issues of importance to European industry, availability of researches with a sufficient record of scientific and industry – related achievements, with special focus on industries important for Orlen Oil, laboratory equipment, selected credentials, etc. As a result of their work we identified at first stage four entities satisfying our criteria. Later others were added.
The two latter were (and still are) recognized as scientific research institutes. This agreements have been serving as an umbrella for transferring numerous technologies under individual contracts, however subjected to some general provisions included to the Agreements. The general provisions covered area of intellectual property rights, exclusivity but also included guidelines for financial terms. Individual contracts then related to specific technologies to be developed and applied. If the final steps were successful technology has been implemented as a part of Orlen Oil portfolio and allowed creation of a new or modified product lines. At the time of my departure there were more than 10 fundamentally new products in the company market portfolio resulting from the scientific researches carried out within the above described agreements. It is worth mentioning that in several cases researches carried out within specific projects gained some scientific interest and results have been published in academic Journals.
Case 3: Resources & Materials Foresight Resources policy has always been and never ceased to be a hot issue. Regardless business you are in materials make it existing. Is Apple really a non-tangible asset based company? Here’s where your iPad (or other modern electronic device) begins: http://www.cnet.com/news/digging-for-rare-earths-the-mines-where-iphones-are-born/ Each CEO? MB? Owner is accountable for a foresight regarding materials used and sold by his company in 10-20 years perspective. Even small and medium size companies will either answer such question and disappear. Not in a moment but it will happen gradually. Is your company ready for the challenge? How to approach it swiftly at in a cost effective manner?
CREDENTIALS & CONSULTING PROJECTS PERFORMED